Genomic and Proteomic Biomarkers for Cardiac and Renal Transplantation: Computational Biomarker Pipeline from Discovery to Clinical Implementation
Conference Recording Jan 07, 2013
About the SpeakerDr. McMaster received a Bachelor and Master of Science from the University of British Columbia (UBC) that was followed by a D.Phil. from the University of Oxford. His research interests are in the areas of molecular immunology, parasitology and transplant immunology and is co-lead on a multi-million initiative “Biomarkers in Transplantation”. Dr. McMaster is a Professor in the Department of Medical Genetics and was Head of the Department, 2000-2010.
Acute graft rejection is an important clinical concern in solid organ transplantation and an adverse predictor for long-term graft survival. The aim of this study is to identify and validate genomic and plasma protein diagnostic markers for acute heart and kidney allograft rejection, and to monitor timely and effective therapeutic intervention to minimize graft damage and enable knowledgeable adjustment of immunosuppressive therapy. We propose a computational proteomic biomarker pipeline, founded on the combination of advanced statistical methodologies. At the discovery stage the computational pipeline emphasizes different aspects of the experimental design, appropriate statistical methodologies, and quality assessment of results. At the validation stage, the computational pipeline focuses on the development an appropriate platform for an external validation, the corroboration of the candidate markers, and the development of a classifier score based on corroborated genomic and proteomic biomarkers for validation in external cohorts. Multiplex assays for both genomic and proteomic biomarkers are being developed for FDA approval for implementation in clinical laboratories. Additionally, the computational methodologies proposed in this pipeline provide a reference to a wide range of biomarker proteomic studies.